[{"id":"442d5c06-75a4-48d9-85ea-9b9fc557a2ef","acronym":"INSIGHT","url":"https://clinicaltrials.gov/study/NCT03252938","created_at":"2021-01-17T17:46:57.179Z","updated_at":"2025-02-25T15:10:38.137Z","phase":"Phase 1","brief_title":"Feasibility and Safety of IMP321 (eftilagimod Alpha) for Advanced Stage Solid Tumors","source_id_and_acronym":"NCT03252938 - INSIGHT","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • ImmuFact (eftilagimod alpha)"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 08/15/2017","start_date":" 08/15/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-13"},{"id":"9769a239-dda3-451c-affd-0604dae6b7e4","acronym":"TACTI 002","url":"https://clinicaltrials.gov/study/NCT03625323","created_at":"2021-01-17T17:19:46.423Z","updated_at":"2025-02-25T16:08:11.649Z","phase":"Phase 2","brief_title":"Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC","source_id_and_acronym":"NCT03625323 - TACTI 002","lead_sponsor":"Immutep S.A.S.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)"],"overall_status":"Completed","enrollment":" Enrollment 187","initiation":"Initiation: 02/18/2019","start_date":" 02/18/2019","primary_txt":" Primary completion: 06/02/2022","primary_completion_date":" 06/02/2022","study_txt":" Completion: 11/25/2024","study_completion_date":" 11/25/2024","last_update_posted":"2024-12-18"},{"id":"4643a56d-2068-41bc-9998-b846c8a36b96","acronym":"KEYNOTE-C34","url":"https://clinicaltrials.gov/study/NCT04811027","created_at":"2021-03-23T11:52:10.624Z","updated_at":"2025-02-25T16:11:17.415Z","phase":"Phase 2","brief_title":"Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC","source_id_and_acronym":"NCT04811027 - KEYNOTE-C34","lead_sponsor":"Immutep S.A.S.","biomarkers":" CTLA4","pipe":" | ","alterations":" PD-L1 expression","tags":["CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 08/27/2021","start_date":" 08/27/2021","primary_txt":" Primary completion: 03/11/2024","primary_completion_date":" 03/11/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-10-31"}]